SaNOtize, Lupin In Legal Row Concerning COVID-19 Nasal Spray
Executive Summary
Canada-based biotech firm SaNOtize and Lupin battle it out in court over alleged breach of confidentiality and copyright infringement in a case concerning their nitric oxide nasal spray for COVID-19.
You may also be interested in...
Canadian Firm Explores Potential Of Nasal Spray In COVID-19 Prevention
Dr Gilly Regev, CEO of the anti-infectives-focused firm, SaNOtize Research & Development Corp, remains confident of the effectiveness of the firm’s nitric oxide nasal spray against evolving variants of SARS-CoV-2 and expects to progress plans for a “prevention” trial in the US.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.